Fore Pharmas latest report ‘Global Overactive Bladder Drug Pipeline Capsule – 2011 is an outline of all the key research and development (R&D) activities of the global overactive bladder drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the overactive bladder drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:
- Overactive Bladder: Overview
- Overactive Bladder Drug Pipeline Overview
- Overactive Bladder Phase 3 Clinical Trial Drug Pipeline Insights
- Overactive Bladder Phase 2 Clinical Trial Drug Pipeline Insights
- Overactive Bladder Phase 1 Clinical Trial Drug Pipeline Insights
- Overactive Bladder Preclinical Research Drug Pipeline Insights
- Overactive Bladder Drug Discovery Pipeline Insights
- Geographic Landscape of Overactive Bladder R&D Activities
- Overactive Bladder R&D Activities in North America
- Overactive Bladder R&D Activities in Europe
- Licensing Activities / Partnerships in the Global Overactive Bladder Drug Market

1. Overactive Bladder: Disease Definition
2. Overactive Bladder Drug Pipeline Overview
3. Overactive Bladder Phase 3 Clinical Trial Drug Pipeline Insights
4. Overactive Bladder Phase 2 Clinical Trial Drug Pipeline Insights
5. Overactive Bladder Phase 1 Clinical Trial Drug Pipeline Insights
6. Overactive Bladder Preclinical Research Drug Pipeline Insights
7. Overactive Bladder Drug Discovery Pipeline Insights
8. Geographic Landscape of Overactive Bladder R&D Activities
8.1 Overactive Bladder R&D Activities in North America
8.2 Overactive Bladder R&D Activities in Europe
9 Licensing Activities / Partnerships in the Global Overactive Bladder Drug Market
10 Research Methodology Table 1: Overactive Bladder Drug Pipeline: Phase 3 Clinical Trial

Table 2: Overactive Bladder Drug Pipeline: Phase 2 Clinical Trial
Table 3: Overactive Bladder Drug Pipeline: Phase 1 Molecules
Table 4: Overactive Bladder Drug Pipeline: Preclinical Research
Table 5: Overactive Bladder R&D Activities by Geography
Table 6: Overactive Bladder Drug Pipeline: North America
Table 7: Overactive Bladder Drug Pipeline: Europe
Table 8: Overactive Bladder Drug Pipeline: Licensing Activities

 Figure 1 : Overactive Bladder Drug Pipeline Molecules by Stages
Figure 2 : Overactive Bladder R&D Activities by Geography